204 related articles for article (PubMed ID: 7520169)
21. Serum cytokeratins determination in differentiated thyroid carcinoma.
Appetecchia M; Meçule A; Ducci M; Palma L; Castelli M
J Exp Clin Cancer Res; 2001 Jun; 20(2):253-6. PubMed ID: 11484983
[TBL] [Abstract][Full Text] [Related]
22. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction.
Bernet VJ; Anderson J; Vaishnav Y; Solomon B; Adair CF; Saji M; Burman KD; Burch HB; Ringel MD
J Clin Endocrinol Metab; 2002 Oct; 87(10):4792-6. PubMed ID: 12364475
[TBL] [Abstract][Full Text] [Related]
23. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
25. Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma.
Schelfhout LJ; Van Muijen GN; Fleuren GJ
Am J Clin Pathol; 1989 Nov; 92(5):654-8. PubMed ID: 2479256
[TBL] [Abstract][Full Text] [Related]
26. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
27. Blood group antigens in differentiated thyroid neoplasms.
González-Cámpora R; García-Sanatana JA; Jordà i Heras MM; Salaverri CO; Vázquez-Ramírez FJ; Argueta-Manzano OE; Galera-Davidson H
Arch Pathol Lab Med; 1998 Nov; 122(11):957-65. PubMed ID: 9822123
[TBL] [Abstract][Full Text] [Related]
28. Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas.
Heyl J; Mehregan D
J Cutan Pathol; 2008 Jan; 35(1):40-5. PubMed ID: 18095993
[TBL] [Abstract][Full Text] [Related]
29. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
30. p63 as a complimentary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions.
Shiran MS; Tan GC; Sabariah AR; Rampal L; Phang KS
Med J Malaysia; 2007 Mar; 62(1):36-9. PubMed ID: 17682568
[TBL] [Abstract][Full Text] [Related]
31. Telomerase activity in "suspicious" thyroid cytology.
Lerma E; Mora J
Cancer; 2005 Dec; 105(6):492-7. PubMed ID: 16104043
[TBL] [Abstract][Full Text] [Related]
32. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.
Puskas LG; Juhasz F; Zarva A; Hackler L; Farid NR
Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(2):177-86. PubMed ID: 16171553
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM
Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
[TBL] [Abstract][Full Text] [Related]
34. [Immunohistochemical analysis of malignant tumors of the thyroid gland using 6 relevant markers].
Brasanac D; Jancić-Zgurics M; Janković R; Tatić S
Srp Arh Celok Lek; 1993; 121(3-7):70-3. PubMed ID: 7716641
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
[TBL] [Abstract][Full Text] [Related]
36. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
37. Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy.
Máximo V; Lima J; Soares P; Botelho T; Gomes L; Sobrinho-Simões M
Mitochondrion; 2005 Oct; 5(5):333-40. PubMed ID: 16183030
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemistry of thyroid carcinoma--an experience with thyroglobulin and calcitonin.
Kavishwar VS; Phatak AM; Rege JD
Indian J Pathol Microbiol; 1998 Apr; 41(2):163-7. PubMed ID: 9670628
[TBL] [Abstract][Full Text] [Related]
39. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
[TBL] [Abstract][Full Text] [Related]
40. Immunoreactivity for cytokeratin and epithelial membrane antigen in leiomyosarcoma.
Miettinen M
Arch Pathol Lab Med; 1988 Jun; 112(6):637-40. PubMed ID: 2454091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
